Anti-C1q antibodies in systemic lupus erythematosus

A-M Orbai; L Truedsson; G Sturfelt; O Nived; H Fang; Gs Alarcón; C Gordon; Jt Merrill; Pr Fortin; In Bruce; DA Isenberg; Dj Wallace; R Ramsey-Goldman; S-C Bae; Jg Hanly; J Sanchez-Guerrero; Ae Clarke; Cb Aranow; S Manzi; Mb Urowitz; Dd Gladman; Kc Kalunian; Mi Costner; Vp Werth; A Zoma; S Bernatsky; G Ruiz-Irastorza; Ma Khamashta; S Jacobsen; Jp Buyon; P Maddison; Ma Dooley; Rf Van Vollenhoven; E Ginzler; T Stoll; C Peschken; Jl Jorizzo; Jp Callen; Ss Lim; Bj Fessler; M Inanc; Dl Kamen; A Rahman; K Steinsson; Ag Franks; L Sigler; S Hameed; N Pham; R Brey; Mh Weisman; G McGwin; Ls Magder; M Petri

doi:10.1177/0961203314547791

Anti-C1q antibodies in systemic lupus erythematosus

A-M Orbai, L Truedsson, G Sturfelt, O Nived, H Fang, Gs Alarcón, C Gordon, Jt Merrill, Pr Fortin, In Bruce, DA Isenberg, Dj Wallace, R Ramsey-Goldman, S-C Bae, Jg Hanly, J Sanchez-Guerrero, Ae Clarke, Cb Aranow, S Manzi, Mb UrowitzDd Gladman, Kc Kalunian, Mi Costner, Vp Werth, A Zoma, S Bernatsky, G Ruiz-Irastorza, Ma Khamashta, S Jacobsen, Jp Buyon, P Maddison, Ma Dooley, Rf Van Vollenhoven, E Ginzler, T Stoll, C Peschken, Jl Jorizzo, Jp Callen, Ss Lim, Bj Fessler, M Inanc, Dl Kamen, A Rahman, K Steinsson, Ag Franks, L Sigler, S Hameed, N Pham, R Brey, Mh Weisman, G McGwin, Ls Magder, M Petri

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

74 Citations (Scopus)

Abstract

OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.

METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.

RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).

CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

Original language	English
Journal	Lupus
DOIs	https://doi.org/10.1177/0961203314547791
Publication status	Published - 14 Aug 2014

Bibliographical note

Access to Document

10.1177/0961203314547791

Cite this

Orbai, A-M., Truedsson, L., Sturfelt, G., Nived, O., Fang, H., Alarcón, G., Gordon, C., Merrill, J., Fortin, P., Bruce, I., Isenberg, DA., Wallace, D., Ramsey-Goldman, R., Bae, S-C., Hanly, J., Sanchez-Guerrero, J., Clarke, A., Aranow, C., Manzi, S., ... Petri, M. (2014). Anti-C1q antibodies in systemic lupus erythematosus. Lupus. https://doi.org/10.1177/0961203314547791

@article{e5b89fc25c574d6690bef17ca5381bc5,

title = "Anti-C1q antibodies in systemic lupus erythematosus",

abstract = "OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.",

author = "A-M Orbai and L Truedsson and G Sturfelt and O Nived and H Fang and Gs Alarc{\'o}n and C Gordon and Jt Merrill and Pr Fortin and In Bruce and DA Isenberg and Dj Wallace and R Ramsey-Goldman and S-C Bae and Jg Hanly and J Sanchez-Guerrero and Ae Clarke and Cb Aranow and S Manzi and Mb Urowitz and Dd Gladman and Kc Kalunian and Mi Costner and Vp Werth and A Zoma and S Bernatsky and G Ruiz-Irastorza and Ma Khamashta and S Jacobsen and Jp Buyon and P Maddison and Ma Dooley and {Van Vollenhoven}, Rf and E Ginzler and T Stoll and C Peschken and Jl Jorizzo and Jp Callen and Ss Lim and Bj Fessler and M Inanc and Dl Kamen and A Rahman and K Steinsson and Ag Franks and L Sigler and S Hameed and N Pham and R Brey and Mh Weisman and G McGwin and Ls Magder and M Petri",

note = "{\textcopyright} The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.",

year = "2014",

month = aug,

day = "14",

doi = "10.1177/0961203314547791",

language = "English",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications",

}

Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, G, Gordon, C, Merrill, J, Fortin, P, Bruce, I, Isenberg, DA, Wallace, D, Ramsey-Goldman, R, Bae, S-C, Hanly, J, Sanchez-Guerrero, J, Clarke, A, Aranow, C, Manzi, S, Urowitz, M, Gladman, D, Kalunian, K, Costner, M, Werth, V, Zoma, A, Bernatsky, S, Ruiz-Irastorza, G, Khamashta, M, Jacobsen, S, Buyon, J, Maddison, P, Dooley, M, Van Vollenhoven, R, Ginzler, E, Stoll, T, Peschken, C, Jorizzo, J, Callen, J, Lim, S, Fessler, B, Inanc, M, Kamen, D, Rahman, A, Steinsson, K, Franks, A, Sigler, L, Hameed, S, Pham, N, Brey, R, Weisman, M, McGwin, G, Magder, L & Petri, M 2014, 'Anti-C1q antibodies in systemic lupus erythematosus', Lupus. https://doi.org/10.1177/0961203314547791

TY - JOUR

T1 - Anti-C1q antibodies in systemic lupus erythematosus

AU - Orbai, A-M

AU - Truedsson, L

AU - Sturfelt, G

AU - Nived, O

AU - Fang, H

AU - Alarcón, Gs

AU - Gordon, C

AU - Merrill, Jt

AU - Fortin, Pr

AU - Bruce, In

AU - Isenberg, DA

AU - Wallace, Dj

AU - Ramsey-Goldman, R

AU - Bae, S-C

AU - Hanly, Jg

AU - Sanchez-Guerrero, J

AU - Clarke, Ae

AU - Aranow, Cb

AU - Manzi, S

AU - Urowitz, Mb

AU - Gladman, Dd

AU - Kalunian, Kc

AU - Costner, Mi

AU - Werth, Vp

AU - Zoma, A

AU - Bernatsky, S

AU - Ruiz-Irastorza, G

AU - Khamashta, Ma

AU - Jacobsen, S

AU - Buyon, Jp

AU - Maddison, P

AU - Dooley, Ma

AU - Van Vollenhoven, Rf

AU - Ginzler, E

AU - Stoll, T

AU - Peschken, C

AU - Jorizzo, Jl

AU - Callen, Jp

AU - Lim, Ss

AU - Fessler, Bj

AU - Inanc, M

AU - Kamen, Dl

AU - Rahman, A

AU - Steinsson, K

AU - Franks, Ag

AU - Sigler, L

AU - Hameed, S

AU - Pham, N

AU - Brey, R

AU - Weisman, Mh

AU - McGwin, G

AU - Magder, Ls

AU - Petri, M

PY - 2014/8/14

Y1 - 2014/8/14

N2 - OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

AB - OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.RESULTS: Prevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).CONCLUSIONS: Anti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

U2 - 10.1177/0961203314547791

DO - 10.1177/0961203314547791

M3 - Article

C2 - 25124676

SN - 0961-2033

JO - Lupus

JF - Lupus

ER -

Anti-C1q antibodies in systemic lupus erythematosus

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this